Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon

This article was originally published in The Pink Sheet Daily

Executive Summary

The unbranded spot tells patients suffering from insomnia to stay tuned for more information coming April 24 about “something on its way that could change your nights.” The ad first aired April 10. Sepracor is also planning to discuss labeling revisions with FDA based on its second six-month trial.

You may also be interested in...



Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says

Sepracor's Lunesta (eszopiclone) "product and use" ad campaign will "be very visible going forward," the company said during its April 25 earnings call

Lunesta Has "Encouraging" Debut, Sepracor Says

For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.

Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says

Sepracor's Lunesta (eszopiclone) "product and use" ad campaign will "be very visible going forward," the company said during its April 25 earnings call

Related Content

Topics

UsernamePublicRestriction

Register

PS061958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel